• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

用伊匹单抗和外用咪喹莫特成功治疗抗纳武单抗的多发卫星灶性黑色素瘤

Successful Treatment of Nivolumab-Resistant Multiple In-Transit Melanomas with Ipilimumab and Topical Imiquimod.

作者信息

Fujimura Taku, Kambayashi Yumi, Sato Yota, Tanita Kayo, Furudate Sadanori, Tsukada Akira, Tono Hisayuki, Hashimoto Akira, Aiba Setsuya

机构信息

Department of Dermatology, Tohoku University Graduate School of Medicine, Sendai, Japan.

出版信息

Case Rep Oncol. 2018 Jan 4;11(1):1-5. doi: 10.1159/000485612. eCollection 2018 Jan-Apr.

DOI:10.1159/000485612
PMID:29515401
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC5836202/
Abstract

Simultaneous or sequential, planned administration of ipilimumab could significantly enhance the antitumor effects of nivolumab in advanced melanoma patients. On the other hand, the efficacy of ipilimumab for nivolumab-resistant advanced melanoma is extremely poor. Therefore, additional supportive therapy for anti-PD-1 antibody therapy-resistant advanced melanoma has been widely investigated. In this report, we describe a case of multiple in-transit melanomas developing in a nivolumab-resistant patient successfully treated with ipilimumab in combination with imiquimod. Our present case suggested a possible therapy for nivolumab-resistant multiple in-transit melanomas using ipilimumab in combination with topical imiquimod.

摘要

同时或序贯、计划性给予伊匹木单抗可显著增强纳武单抗对晚期黑色素瘤患者的抗肿瘤作用。另一方面，伊匹木单抗对纳武单抗耐药的晚期黑色素瘤疗效极差。因此，针对抗程序性死亡蛋白1（PD-1）抗体治疗耐药的晚期黑色素瘤的额外支持性治疗已得到广泛研究。在本报告中，我们描述了1例纳武单抗耐药患者发生多发移行性黑色素瘤，经伊匹木单抗联合咪喹莫特成功治疗的病例。我们目前的病例提示，伊匹木单抗联合外用咪喹莫特可能是治疗纳武单抗耐药多发移行性黑色素瘤的一种疗法。

相似文献

1
Successful Treatment of Nivolumab-Resistant Multiple In-Transit Melanomas with Ipilimumab and Topical Imiquimod.用伊匹单抗和外用咪喹莫特成功治疗抗纳武单抗的多发卫星灶性黑色素瘤
Case Rep Oncol. 2018 Jan 4;11(1):1-5. doi: 10.1159/000485612. eCollection 2018 Jan-Apr.
2
Successful treatment of multiple in-transit melanomas on the leg with intensity-modulated radiotherapy and immune checkpoint inhibitors: Report of two cases.调强放疗联合免疫检查点抑制剂成功治疗腿部多发移行性黑素瘤：2例报告
J Dermatol. 2017 May;44(5):592-595. doi: 10.1111/1346-8138.13707. Epub 2016 Dec 3.
3
Intensity-Modulated Radiotherapy Triggers Onset of Bullous Pemphigoid in a Patient with Advanced Melanoma Treated with Nivolumab.调强放疗引发一名接受纳武单抗治疗的晚期黑色素瘤患者发生大疱性类天疱疮。
Case Rep Oncol. 2018 Feb 15;11(1):114-118. doi: 10.1159/000487127. eCollection 2018 Jan-Apr.
4
Ipilimumab alone or in combination with nivolumab after progression on anti-PD-1 therapy in advanced melanoma.在晚期黑色素瘤患者抗PD-1治疗进展后，使用伊匹单抗单药或与纳武单抗联合治疗。
Eur J Cancer. 2017 Apr;75:47-55. doi: 10.1016/j.ejca.2017.01.009. Epub 2017 Feb 17.
5
Successful Treatment of Unresectable Advanced Melanoma by Administration of Nivolumab With Ipilimumab Before Primary Tumor Resection.在原发性肿瘤切除前给予纳武单抗联合易普利姆玛治疗不可切除的晚期黑色素瘤取得成功。
Front Med (Lausanne). 2019 Jun 26;6:140. doi: 10.3389/fmed.2019.00140. eCollection 2019.
6
Three cases of nivolumab therapy-failed advanced melanoma successfully controlled by ipilimumab with intensity-modulated radiotherapy.三例纳武利尤单抗治疗失败的晚期黑色素瘤经强度调节放疗联合伊匹单抗治疗后得到成功控制。
J Dermatol. 2019 May;46(5):449-452. doi: 10.1111/1346-8138.14861. Epub 2019 Mar 25.
7
A Case of Erythema Multiforme Major Developed after Sequential Use of Two Immune Checkpoint Inhibitors, Nivolumab and Ipilimumab, for Advanced Melanoma: Possible Implication of Synergistic and/or Complementary Immunomodulatory Effects.一例晚期黑色素瘤患者在序贯使用两种免疫检查点抑制剂纳武利尤单抗和伊匹木单抗后发生重症多形红斑：协同和/或互补免疫调节作用的可能影响
Case Rep Dermatol. 2018 Jan 18;10(1):1-6. doi: 10.1159/000485910. eCollection 2018 Jan-Apr.
8
Successful Treatment of a Patient with anti-PD1 Antibody-Resistant Advanced Mucosal Melanoma with Nivolumab, Ipilimumab plus Denosumab Combination Therapy.纳武单抗、伊匹单抗联合地诺单抗治疗抗PD1抗体耐药的晚期黏膜黑色素瘤患者获成功
Case Rep Oncol. 2020 Mar 24;13(1):271-275. doi: 10.1159/000506327. eCollection 2020 Jan-Apr.
9
Neoadjuvant PD-1 Blockade in Resectable Lung Cancer; Nivolumab and Ipilimumab in Advanced Melanoma; Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma; Prolonged Survival in Stage III Melanoma with Ipilimumab Adjuvant Therapy; Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma; Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma; Nivolumab and Ipilimumab versus Ipilimumab in Untreated Melanoma; Rapid Eradication of a Bulky Melanoma Mass with One Dose of Immunotherapy; Genetic Basis for Clinical Response to CTLA-4 Blockade; Genetic Basis for Clinical Response to CTLA-4 Blockade in Melanoma; Nivolumab plus Ipilimumab in Advanced Melanoma; Safety and Tumor Responses with Lambrolizumab (Anti-PD-1) in Melanoma; Hepatotoxicity with Combination of Vemurafenib and Ipilimumab.可切除肺癌的新辅助PD-1阻断；晚期黑色素瘤中的纳武单抗和伊匹单抗；晚期黑色素瘤联合使用纳武单抗和伊匹单抗的总生存期；伊匹单抗辅助治疗Ⅲ期黑色素瘤的生存期延长；未经治疗的黑色素瘤中联合使用纳武单抗和伊匹单抗或单药治疗；未经治疗的黑色素瘤中联合使用纳武单抗和伊匹单抗或单药治疗；未经治疗的黑色素瘤中纳武单抗和伊匹单抗与伊匹单抗对比；一剂免疫疗法快速根除巨大黑色素瘤肿块；CTLA-4阻断临床反应的遗传基础；黑色素瘤中CTLA-4阻断临床反应的遗传基础；晚期黑色素瘤中的纳武单抗加伊匹单抗；黑色素瘤中帕博利珠单抗（抗PD-1）的安全性和肿瘤反应；维莫非尼和伊匹单抗联合使用的肝毒性。
N Engl J Med. 2018 Nov 29;379(22):2185. doi: 10.1056/NEJMx180040. Epub 2018 Nov 9.
10
Successful Treatment of Multiple Metastatic Melanoma with Nivolumab, Ipilimumab plus Denosumab Combined Therapy.纳武单抗、伊匹单抗联合地诺单抗治疗多发性转移性黑色素瘤取得成功
Case Rep Oncol. 2019 Oct 30;12(3):829-833. doi: 10.1159/000504019. eCollection 2019 Sep-Dec.

引用本文的文献

1
Recent progress in topical and transdermal approaches for melanoma treatment.黑色素瘤治疗的局部和透皮方法的最新进展。
Drug Deliv Transl Res. 2025 May;15(5):1457-1495. doi: 10.1007/s13346-024-01738-z. Epub 2024 Dec 9.
2
Host-pathogen protein-nucleic acid interactions: A comprehensive review.宿主-病原体蛋白-核酸相互作用：全面综述。
Comput Struct Biotechnol J. 2022 Aug 4;20:4415-4436. doi: 10.1016/j.csbj.2022.08.001. eCollection 2022.
3
Is There a Place for Immune Checkpoint Inhibitors in Vulvar Neoplasms? A State of the Art Review.

本文引用的文献

1
Retrospective study of advanced melanoma patients treated with ipilimumab after nivolumab: Analysis of 60 Japanese patients.纳武利尤单抗治疗后接受伊匹单抗治疗的晚期黑色素瘤患者的回顾性研究：60 例日本患者分析。
J Dermatol Sci. 2018 Jan;89(1):60-66. doi: 10.1016/j.jdermsci.2017.10.009. Epub 2017 Oct 25.
2
Phase I study of nivolumab combined with IFN-β for patients with advanced melanoma.纳武单抗联合干扰素-β治疗晚期黑色素瘤患者的I期研究。
Oncotarget. 2017 Apr 13;8(41):71181-71187. doi: 10.18632/oncotarget.17090. eCollection 2017 Sep 19.
3
Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma.
免疫检查点抑制剂在外阴肿瘤中的应用前景？一项综述。
Int J Mol Sci. 2020 Dec 27;22(1):190. doi: 10.3390/ijms22010190.
4
Targeting nuclear acid-mediated immunity in cancer immune checkpoint inhibitor therapies.靶向癌症免疫检查点抑制剂治疗中的核酸介导免疫。
Signal Transduct Target Ther. 2020 Nov 20;5(1):270. doi: 10.1038/s41392-020-00347-9.
5
Topical and intralesional therapies for in-transitmelanoma.肢端转移黑色素瘤的局部和病损内治疗。
Melanoma Manag. 2019 Sep 2;6(3):MMT23. doi: 10.2217/mmt-2019-0008.
6
Diagnosis and Management of Acral Lentiginous Melanoma.肢端雀斑样黑素瘤的诊断与治疗。
Curr Treat Options Oncol. 2018 Jun 27;19(8):42. doi: 10.1007/s11864-018-0560-y.
纳武利尤单抗联合伊匹木单抗治疗晚期黑色素瘤的总生存期
N Engl J Med. 2017 Oct 5;377(14):1345-1356. doi: 10.1056/NEJMoa1709684. Epub 2017 Sep 11.
4
Immunomodulatory Effect of Imiquimod Through CCL22 Produced by Tumor-associated Macrophages in B16F10 Melanomas.咪喹莫特通过肿瘤相关巨噬细胞产生的CCL22对B16F10黑色素瘤的免疫调节作用
Anticancer Res. 2017 Jul;37(7):3461-3471. doi: 10.21873/anticanres.11714.
5
Successful treatment of multiple in-transit melanomas on the leg with intensity-modulated radiotherapy and immune checkpoint inhibitors: Report of two cases.调强放疗联合免疫检查点抑制剂成功治疗腿部多发移行性黑素瘤：2例报告
J Dermatol. 2017 May;44(5):592-595. doi: 10.1111/1346-8138.13707. Epub 2016 Dec 3.
6
Sequential administration of nivolumab and ipilimumab with a planned switch in patients with advanced melanoma (CheckMate 064): an open-label, randomised, phase 2 trial.纳武利尤单抗和伊匹木单抗序贯给药并计划在晚期黑色素瘤患者中进行转换（CheckMate 064）：一项开放标签、随机、2期试验。
Lancet Oncol. 2016 Jul;17(7):943-955. doi: 10.1016/S1470-2045(16)30126-7. Epub 2016 Jun 4.
7
Treatment of in-transit and metastatic melanoma in two patients treated with ipilimumab and topical imiquimod.两名接受伊匹单抗和局部咪喹莫特治疗的患者的局部转移和转移性黑色素瘤的治疗。
Melanoma Res. 2016 Aug;26(4):409-12. doi: 10.1097/CMR.0000000000000247.
8
Melanoma in situ: Part II. Histopathology, treatment, and clinical management.原位黑素瘤：第二部分。组织病理学、治疗和临床管理。
J Am Acad Dermatol. 2015 Aug;73(2):193-203; quiz 203-4. doi: 10.1016/j.jaad.2015.03.057.
9
Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma.纳武利尤单抗与伊匹木单抗联合用药或单药治疗初治黑色素瘤
N Engl J Med. 2015 Jul 2;373(1):23-34. doi: 10.1056/NEJMoa1504030. Epub 2015 May 31.
10
Effective innate and adaptive antimelanoma immunity through localized TLR7/8 activation.通过局部激活TLR7/8实现有效的先天性和适应性抗黑色素瘤免疫。
J Immunol. 2014 Nov 1;193(9):4722-31. doi: 10.4049/jimmunol.1401160. Epub 2014 Sep 24.